UT-XLEAR
1.11.2021 12:32:10 CET | Business Wire | Press release
Today, Nathan Jones, CEO of Xlear, Inc. released this statement in response to a lawsuit filed by the Department of Justice, on behalf of the United States, alleging that certain statements made by Xlear violated the Federal Trade Commission Act and the Consumer Protection Act:
Last year, the Government published on the website of the National Institutes of Health the results of a clinical trial performed by researchers at Larkin Community Hospital, Florida. The Larkin clinical trial found people who were already sick with COVID-19, who used Xlear nasal spray—and just Xlear nasal spray—cleared the disease and tested negative in half the time of the average COVID-19 case. None of the patients developed severe cases, none required hospitalization. Now the Government is suing Xlear asserting, among other things, that when Xlear tells people about scientific studies, even ones republished by the NIH, we are somehow misleading people and making false claims. It’s nonsensical.
What is more troubling, despite the results of the Larkin trial, and despite the results of a Government-funded Random Clinical Trial done at Vanderbilt University, and despite the findings of yet another Random Clinical Trial done in Georgia, the Government refuses to tell the American people that washing your nose may significantly reduce your risks of getting a severe case of COVID-19, which could result in hospitalization and death.
At the same time, growing numbers of in vitro studies find Xlear, and its components, are: antiviral (blocks adhesion—infection—by COVID-19); virucidal (kills and/or deactivates the COVID-19 virus); and, antibacterial (help prevent pneumonia, a leading COVID-19 co-morbidity). This is real science—done and published by independent medical experts. We believe so strongly in the science we are providing links to these studies here. People should read them for themselves.
In sharp contrast to trying to protect the American public, the Government is doing all in its power to stop Xlear from simply telling the public about the science. It is profoundly ironic that the Government, which now constantly ignores science for political reasons, suggests that it is taking this action against Xlear to somehow protect the people. From what is the Government protecting Americans? From the facts. From the science. From their right to know.
Notwithstanding the Government’s litany of failures in protecting Americans from COVID-19, the Government seeks to pin blame on Xlear, a small company trying to help Americans understand there are other things that you can do that may help to provide additional layer of protection against COVID-19 for you, your friends, and your family. Get vaccinated, wear a mask, social distance, use common-sense, wash your hands—and wash your nose.
The Government tells people to wash their hands; Yet COVID-19 is an upper respiratory illness. Most COVID-19 infections start in the nose. It makes commonsense to wash your nose. People have been using nasal cleansing to fight respiratory illnesses going back thousands of years.
Xlear denies the Government’s allegations. We will vigorously defend against the Government’s case, and, in doing so, defend the science against politics, paternalism, and dogmaticism.
References:
Go , Camille Celeste, Pandav, Krunal, Sanchez-Gonzalez, Marcos A, Ferrer Gustavo, Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series (Nov. 2020), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645297/
Ferrer, Gustavo, et al, A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-Cov-2 In Vitro, BioRxiv (Nov. 25, 2020), available at https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
;
Cannon, Mark, et al, In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2, bioRxiv 2020.12.02.408575, available at https://www.biorxiv.org/content/10.1101/2020.12.02.408575v2.full.pdf+html
;
Ferrer, G., et al., In Vitro Analysis of the Anti-viral Potential of Nasal Spray Constituents Xylitol and Grapefruit Extract plus against SARS-CoV-2, forthcoming in Journal Virus Research;
Kimura, K., et al., Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in nonhospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. 2020; 10: 1325– 1328, available at https://pubmed.ncbi.nlm.nih.gov/32914928/
.
Amy Baxter, et al., Rapid initiation of nasal saline irrigation to reduce morbidity and mortality in COVID+ outpatients: a randomized clinical trial compared to a national dataset, medRxiv 2021.08.16.21262044; doi:https://doi.org/10.1101/2021.08.16.21262044
available at https://www.medrxiv.org/content/10.1101/2021.08.16.21262044v2
;
Cegolon L, Javanbakht M, Mastrangelo G. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents [published online ahead of print, 2020 Aug 18]. Int J Hyg Environ Health. 2020;230:113605. doi:10.1016/j.ijheh.2020.113605;
Lipworth B, Chan R, RuiWen Kuo C. COVID-19: Start with the nose. J Allergy Clin Immunol. 2020;146(5):1214. doi:10.1016/j.jaci.2020.06.038; Spinelli, M. et al., Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity, The Lancet, Feb. 22, 2020, available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30982-8/fulltext
;
Radulesco T, Lechien JR, Saussez S, Hopkins C, Michel J. Safety and Impact of Nasal Lavages During Viral Infections Such as SARS-CoV-2. Ear Nose Throat J. 2021;100(2_suppl):188S-191S. doi:10.1177/0145561320950491.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005329/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck Debuts New Family Bundle Ticket Options13.7.2026 22:30:00 CEST | Press release
Groups of four can save up to 20% on Observation Deck tickets purchased online The Empire State Building Observation Deck (ESBOD), atop the “World’s Most Famous Building,” announced today new ticket bundle options for families of all ages to save on their visit to the famed New York City landmark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713003884/en/ Empire State Building Observation Deck Debuts New Family Bundle Ticket Options Groups of four who purchase the new Family Ticket Bundle can save up to 20 percent on tickets to the Empire State Building’s iconic 86th and 102nd Floor Observation Decks, with options for express access and flex admission. The Family Ticket Bundle is available online only. “The Empire State Building Observation Deck is one of the best activities for families in NYC with immersive, educational museum exhibits and Manhattan’s best skyline views,” said Dan Rogoski, observatory general manager.
Kinaxis Inc. to Host Second Quarter 2026 Financial Results Conference Call on August 6, 202613.7.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that it has scheduled a conference call to discuss its financial results for the second quarter ended June 30, 2026. The call will be hosted on Thursday, August 6, 2026, at 8:30 a.m. Eastern Time by Razat Gaurav, Chief Executive Officer, and Peter Yaraskavitch, Vice President, Financial Planning and Analysis, followed by a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Wednesday, August 5, 2026. CONFERENCE CALL DETAILS DATE: Thursday, August 6, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/854228135 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietar
PagerDuty Announces Arnaud Lagarde, Vice President of EMEA13.7.2026 22:05:00 CEST | Press release
PagerDuty, Inc. (NYSE: PD), a leader in AI-first operations management, today announced the appointment of Arnaud Lagarde as vice president of EMEA. Lagarde will lead PagerDuty’s next phase of growth in the EMEA region, bringing the entire incident management lifecycle to customers across EMEA to solve their biggest digital challenges. “We are thrilled to appoint Arnaud as vice president of EMEA, since he brings a wealth of enterprise sales relationships and years of experience growing this region,” said Todd McNabb, chief revenue officer at PagerDuty. “Arnaud brings a specific combination of deep technical expertise and leadership that will be critical for PagerDuty’s customers, partners and employees. He is a great fit for PagerDuty and we look forward to his impact.” Lagarde brings to the role over 20 years of experience spanning companies like Automation Anywhere, CA Technologies and BMC. Over the past two decades, he has worked closely with founders, investors and executive teams
Samos Energy Acquisition Corporation Announces Closing of $230 Million Initial Public Offering13.7.2026 21:42:00 CEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the closing of its initial public offering (“IPO”) of 23,000,000 units, including the full exercise by the underwriters of their overallotment option to purchase an additional 3,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds to the Company of $230,000,000. The units began trading on the New York Stock Exchange (the “NYSE”) under the ticker symbol “SAMO.U” on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Of the proceeds received from the consummation of the initial public offerin
Kina, EU-respondenter optimistiske om fremtidsudsigterne for samarbejde: GT survey13.7.2026 20:46:00 CEST | Pressemeddelelse
Kina og EU har haft etablerede diplomatiske forbindelser i mere end et halvt århundrede. Fra etableringen af formelle diplomatiske forbindelser til udviklingen til et omfattende strategisk partnerskab er Kina-EU-forbindelserne blevet et af de mest indflydelsesrige bilaterale forhold i verden i dag. Ud over Kina gennemførte Global Times Institute (GTI) fra den 16. oktober til den 4. november 2025 en spørgeskemaundersøgelse i 20 EU-medlemsstater, herunder Danmark, Sverige, Spanien, Belgien og Tyskland, ved hjælp af 21 sprog som spansk, fransk, tysk og kinesisk. Mere end 16.300 gyldige spørgeskemaer blev indsamlet. Undersøgelsesdataene viser, at et flertal af befolkningen i både Kina og EU er interesserede i hinandens kulturer, har stor tillid til fremtiden for det kinesisk-europæiske økonomiske og handelsmæssige samarbejde, og støtter styrket samarbejde mellem Kina og EU inden for global styring. Høj grad af bevidsthed og vilje til kommunikation Denne undersøgelse viser, at befolkningen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
